Search
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnInterferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the mos...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsOctreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalAcromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the f...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsEnfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesCalcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalCalcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D3. It is produced in the body after series...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersGlutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalA tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Flunisolide
go.drugbank.com/drugs/DB00180ApprovedFlunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersCevimeline
go.drugbank.com/drugs/DB00185ApprovedCevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigationalBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesBetaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Synonyms: 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTroglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates